Whitehawk Therapeutics (WHWK) Accumulated Expenses (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Accumulated Expenses data on file, last reported at $9.3 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 8.05% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 8.05% increase from a year earlier, with the FY2025 full-year figure at $192000.0, down 98.69% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $9.3 million, up from $192000.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for WHWK reached as high as $14.9 million in Q4 2022 and fell as low as $192000.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $9.3 million across 5 years, with a median of $10.6 million in 2024.
• Across the five-year window, Accumulated Expenses soared 1176.46% in 2022 and tumbled 98.69% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $14.9 million in 2022, then retreated by 4.13% to $14.3 million in 2023, then advanced by 2.38% to $14.6 million in 2024, then tumbled by 98.69% to $192000.0 in 2025, then surged by 4749.48% to $9.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $9.3 million in Q1 2026, $192000.0 in Q4 2025, and $700000.0 in Q3 2025.